• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort
EClinicalMedicine. 2023 Jul 21;62:102107. doi: 10.1016/j.eclinm.2023.102107. eCollection 2023 Aug.ABSTRACTBACKGROUND: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs.METHODS: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant o...
Source: Cell Research - September 1, 2023 Category: Cytology Authors: Elisa Gentilotti Anna G órska Adriana Tami Roy Gusinow Massimo Mirandola Jes ús Rodríguez Baño Zaira R Palacios Baena Elisa Rossi Jan Hasenauer Iris Lopes-Rafegas Elda Righi Natascia Caroccia Salvatore Cataudella Zeno Pasquini Thomas Osmo Lidia Del Pi Source Type: research

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news

Acute Uveitis Following AstraZeneca COVID-19 Vaccination
CONCLUSION: Our case highlights the possibility of uveitis as an ocular complication of Oxford-AstraZeneca COVID-19 vaccination.PMID:37023373 | DOI:10.1080/09273948.2023.2189456
Source: Ocular Immunology and Inflammation - April 6, 2023 Category: Allergy & Immunology Authors: Sae Kyung Cho Xia Ni Wu Chathri Amaratunge Source Type: research

Subacute thyroiditis following COVID-19: A systematic review
ConclusionSAT secondary to COVID-19 seems to manifest almost similarly to the conventional SAT. However, except for the case reports and case series, lack of studies has limited the quality of the data at hand.
Source: Frontiers in Endocrinology - April 5, 2023 Category: Endocrinology Source Type: research

Acquired hemophilia A following COVID-19 vaccine: a case report
ConclusionClinicians should consider AHA in front of prolonged aPTT with or without spontaneous bleedings even after inactivated virus COVID-19.
Source: Journal of Medical Case Reports - March 27, 2023 Category: General Medicine Source Type: research

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

COVID-19 Vaccine –Related Myocardial and Pericardial Inflammation
AbstractPurpose of ReviewTo review myocarditis and pericarditis developing after COVID-19 vaccinations and identify the management strategies.Recent FindingsCOVID-19 mRNA vaccines are safe and effective. Systemic side effects of the vaccines are usually mild and transient. The incidence of acute myocarditis/pericarditis following COVID-19 vaccination is extremely low and ranges 2 –20 per 100,000. The absolute number of myocarditis events is 1–10 per million after COVID-19 vaccination as compared to 40 per million after a COVID-19 infection. Higher rates are reported for pericarditis and myocarditis in COVID-19 infectio...
Source: Current Cardiology Reports - November 28, 2022 Category: Cardiology Source Type: research

Myocarditis Following COVID ‐19 Vaccine: Incidence, Presentation, Diagnosis, Pathophysiology, Therapy, and Outcomes put into Perspective
This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - September 6, 2022 Category: Cardiology Authors: Bettina Heidecker, Noa Dagan, Ran Balicer, Urs Eriksson, Giuseppe Rosano, Andrew Coats, Carsten Tsch öpe, Sebastian Kelle, Gregory A. Poland, Andrea Frustaci, Karin Klingel, Pilar Martin, Joshua Hare, Leslie Cooper, Antonis Pantazis, Massi Tags: Review Article Source Type: research

A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax < sup > ® < /sup > ) COVID-19 Vaccination
We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vacc...
Source: Journal of Korean Medical Science - August 29, 2022 Category: Biomedical Science Authors: Hyung Yoon Kim Jae Yeong Cho Hyun Ju Yoon Yoo-Duk Choi Youngkeun Ahn Myung Ho Jeong Jeong Gwan Cho Kye Hun Kim Source Type: research

Pages: 1  2